[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100634836":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":10,"centralContacts":19,"locations":25,"responsibleParty":41,"collaborators":10,"id":43,"slug":10,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":10,"eligibilityCriteria":48,"healthyVolunteers":44,"sex":49,"minAge":50,"maxAge":10,"enrollmentInfo":51,"targetDuration":54,"studyType":55,"phases":10,"briefSummary":56,"conditions":57,"keywords":10,"overallStatus":28,"whyStopped":10,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},{"fullName":5,"class":6},"Chengdu Kangnuoxing Biopharma,Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"Group of Stapokibart Injection",null,[12],"Biological: Stapokibart",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"BIOLOGICAL","Stapokibart","subcutaneous injection",[9],[20],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Qian Jia","CONTACT","028-88610620","clinicaltrial@keymedbio.com",[26],{"facility":27,"status":28,"city":29,"state":30,"zip":10,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Peking University People's Hospital","RECRUITING","Beijing","Beijing Municipality","China","CN",{"type":34,"coordinates":35},"Point",[36,37],116.39723,39.9075,{"lat":37,"lon":36},[40],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},{"type":42,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100634836",false,"NCT07544862","A Study of Stapokibart Injection in Patients With Atopic Dermatitis (AD)","A Prospective Study of Stapokibart Injection in Patients With Moderate-to-Severe Atopic Dermatitis (AD)","Inclusion Criteria:\n\n* Trial participants aged 18 years or older at baseline, with no restrictions on gender.\n* Physician decision to treat trial participants with Stapokibart Injection for AD (according to the China-specific prescribing information) made prior to and independently of the participant's participation in the study.\n\nExclusion Criteria:\n\n* Known history of allergic reaction to Stapokibart Injection.\n* Trial participants currently or plan participating in any interventional clinical trial.\n* Trial participants with hematologic malignancies.\n* Women with pregnant.\n* Any condition that, in the opinion of the investigator, may interfere with trial participants' ability to participate in the study.","ALL","18 Years",{"count":52,"type":53},1000,"ESTIMATED","52 Weeks","OBSERVATIONAL","This study is an open label, prospective study to evaluate the safety and efficacy of Stapokibart Injection in patients with AD.",[58],"Atopic Dermatitis (AD)","2026-06-08",{"date":61,"type":62},"2026-06-10","ACTUAL",{"date":64,"type":62},"2026-06-02",{"date":66,"type":53},"2028-02",{"name":5,"class":6},1]